Antengene has become the fourth Chinese biopharmaceutical company in less than a year to raise well over $100 million from private investors, illustrating the country's growing efforts to develop effective anti-cancer drugs.
Shanghai-based Antengene said it completed a $120 million Series B fundraising on Wednesday to finance more research and invest in marketing for its ATG-008 anti-cancer drug, which is already undergoing Phase II clinical trials and so is being tried out on patients.
Last year, three other China pharmaceutical companies attracted nine-figure sums including CStone Pharmaceutical $260 million, I-MAB Biopharma $220 million, and...
¬ Haymarket Media Limited. All rights reserved.
